N/A N=43 PureWick™ Adolescent Study
Healthy Volunteers, Adolescent
Primary: Performance of the PureWick System in Adolescents After HCP Placement and Self-placement — 90.40; 93.09; 87.15; 90.41 Percentage of urine captured
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
N/A N=353 Testing a Digital Intervention for Adolescents
Rumination · Stress, Psychological
Primary: Change in Perceived Stress [Perceived Stress Scale (PSS)] — 26.33; 25.26; 22.01; 24.67 score on a scale — p=<.001
Phase 3 N=50 Pharmacokinetics, Safety, and Efficacy of Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Disoproxil Fumarate Single Tablet Regimen (STR) in Adolescents
Acquired Immunodeficiency Syndrome · HIV Infections
Primary: For Part A, Pharmacokinetic (PK) Parameter: AUCtau of EVG — 31620.9 ng•h/mL
Phase 3 N=157 Varenicline for Adolescent Smoking Cessation
Nicotine Dependence
Primary: Number of Participants With Cotinine-confirmed 7-day Point Prevalence Abstinence at the End of Treatment — 4; 4 Participants
Phase 1 N=41 A Study of OsrHSA in Adult Healthy Male and Female Volunteers
Ascites Hepatic
Primary: Incidence of Treatment-Emergent Adverse Events — 1; 0; 2; 1 Participants
Phase 2 N=25 Positron-Emission Tomography With Vesicular Monoamine Transporter Ligand ([18F]-DTBZ) In Healthy Elderly And Young Subjects
Healthy
Primary: Age-Dependent Change in Striatal 18F-DTBZ Uptake of Healthy Subjects. — 0.05 SUVR
Phase 1 N=62 Phase 1 Study of ELX-02 in Healthy Adult Subjects
Genetic Disease · Nonsense Mutation
Primary: Pharmacokinetic Parameters - Plasma AUC0-24 — 1105.126; 3125.484; 11018.22; 28235.823 ng*h/mL
Phase 4 N=423 Immunogenicity of Adacel® and BOOSTRIX® Vaccines in Adolescents
Tetanus · Diphtheria · Pertussis
Primary: Number of Participants With Antibody Responses to Tetanus and Diphtheria Components Following Vaccination With Either Adacel® or BOOSTRIX® Vaccine — 172; 177; 196; 194…
Phase 4 N=312 Smoking Cessation Study In Healthy Adolescent Smokers
Smoking Cessation
Primary: 4-Week Continuous Abstinence Rate: Percentage of Participants Who Remained Abstinent From Week 9 Through Week 12 — 20.2; 27.2; 18.0 percentage of participants — p=0.6337
Phase 2 N=60 Safety and Immunogenicity of a Candidate Tuberculosis (TB) Vaccine in Healthy HIV Negative Adolescents
Tuberculosis
Primary: Number of Subjects With Solicited Local Symptoms — 37; 3; 3; 0 Subjects
Phase 3 N=94 Treximet Early Intervention Adolescent Migraine
Migraine
Primary: Number of Participants With 2-hour Pain Free Active Study Drug — 35; 23; 21; 24 Participants — p=0.0038
Phase 1 N=43 H3N2 M2SR in Pediatric Population
Influenza · Influenza Immunisation
Primary: Number of Participants With Adverse Events of Special Interest (AESIs) — 0; 0 Participants
N/A N=31 Activity, Adiposity, and Appetite in Adolescents 2 Intervention
Obesity · Energy Balance · Appetite
Primary: Appetite- Subjective — 6282; 8738 score*minute
Phase 2 N=583 Peds Sanofi H1N1 Influenza Vaccine Administered at Two Dose Levels
Influenza
Primary: Number of Participants Reporting Solicited Subjective Local Reactions After the First Vaccination — 60; 69; 102; 98 Participants
Phase 3 N=5,712 A Global Phase 3 Safety Study of 120 mcg rLP2086 Vaccine in Adolescents and Young Adults Aged 10 to 25 Years
Meningitis, Meningococcal
Primary: Percentage of Participants With at Least One Serious Adverse Event (SAE) Throughout the Study — 1.55; 2.52 percentage of participants
Phase 4 N=261 Varenicline for Nicotine Vaping Cessation in Adolescents
Vaping · Nicotine Dependence
Primary: Continuous 4-week Nicotine Vaping Abstinence at End of Treatment (Weeks 9-12) — 45; 12; 5 Participants — p=<0.001
Phase 2 N=526 A Phase 2 Randomized Multisite Trial to Inform Public Health Strategies Involving the Use of MVA-BN Vaccine for Mpox
Monkeypox
Primary: Vaccinia Virus Specific Plaque Reduction Neutralization Test (PRNT) Geometric Mean Titer (GMT) — 470.3; 295.7; 293.2 titer — p=<0.001
N/A N=1,095 Adolescent Wellness Visits in Tanzania
HIV Testing · Contraceptive Usage
Primary: Number of Adolescents Who Self-reported HIV Testing and Counseling, Inclusive of the Adolescent Wellness Visit — 234; 86 Participants
N/A N=223 Self-guided Treatment for Adolescents Navigating Depression
Depressive Symptoms · Depression · Depressive Disorder
Primary: Depressive Symptom Severity at Post-intervention — 8.39; 11.03 units on a scale — p=<0.001
Phase 1 N=50 Open-label Safety and Tolerability Study of CoVaccine HT™ in Healthy Volunteers
Vaccine
Primary: Safety Events — 20; 0; 40; 50 percentage of patients
N/A N=16 Active and Passive Music Therapy Interventions
Autonomic Nervous System Imbalance · Hypothalamic Pituitary Adrenal Axis Suppression
Primary: Change From Baseline to Post Intervention High Frequency (HF) and Low Frequency Divided by High Frequency (LF/HF) Power Amplitude — 0.1796; 0.1507; -0.3872; 0.3731…
Phase 1 N=12 A Study to Assess the Safety, Effects and Palatability of Sisunatovir in Healthy Adult Participants
Respiratory Syncytial Viruses
Primary: Number of Participants With Treatment Emergent Adverse Events (TEAEs) — 6; 7; 4; 9 Participants
N/A N=51 Identifying Decision Making Parameters in Healthy Volunteers and Anxiety Patients
Anxiety · Healthy Volunteers
Primary: Difference in Learning Rate — 0.009; 0.0058 unitless
N/A N=515 Prospective Cohort Study of Adolescents Living With HIV and Their Caregivers Attending a Psychosocial Programme in Botswana
Hiv
Primary: Quality of Life/Well-being (Young People) — 4.77 score on a scale
Phase 2 N=96 Study of Thyrotropin-Releasing Hormone in Normal Volunteers and in Patients With Thyroid or Pituitary Abnormalities
Healthy · Pituitary Disease · Thyroid Disease
Primary: TSH Response to TRH — 11.47 mcIU/mL
N/A N=20 Wearable Dark-adaptometer in Normal Adult Healthy Volunteers
Photoreceptor Sensitivity Thresholds
Primary: Time to Rod-cone Break (RCB) — 11.34; 9.98 Minutes
Phase 1 N=66 Phase 1 Study for IPG11406 in Health Volunteer
Inflammatory Bowel Diseases
Primary: Safety Indicators：Adverse Event — 1; 3; 2; 3 Participants
Phase 1 N=24 A Study to Learn About the Study Medicine (PF-07293893) at Different Dose Levels in Healthy Adults
Healthy Participants
Primary: Number of Participants With Treatment Emergent Adverse Events (TEAEs) — 1; 2; 1; 2 Participants
N/A N=56 Vitamin D Supplementation in Healthy Adolescents
Vitamin D Supplementation
Primary: Baseline 25 Hydroxy Vitamin D (25OHD) Levels — 28.1; 29 ng/ml
Phase 1 N=26 VRC 605: Safety and Pharmacokinetics of a Human Monoclonal Antibody, VRC-HIVMAB075-00-AB (VRC07-523LS), Administered Intravenously or Subcutaneously to Healthy Adults
HIV Prevention
Primary: Number of Subjects Reporting Systemic Reactogenicity Signs and Symptoms Within 3 Days of Any Product Administration — 3; 3; 3; 2 Participants